These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 21482348)
1. PROphylaxis for ThromboEmbolism in Critical Care Trial protocol and analysis plan. Cook D; Meade M; Guyatt G; Walter SD; Heels-Ansdell D; Geerts W; Warkentin TE; Cooper DJ; Zytaruk N; Vallance S; Berwanger O; Rocha M; Qushmaq I; Crowther M J Crit Care; 2011 Apr; 26(2):223.e1-9. PubMed ID: 21482348 [TBL] [Abstract][Full Text] [Related]
2. Dalteparin versus unfractionated heparin in critically ill patients. ; Cook D; Meade M; Guyatt G; Walter S; Heels-Ansdell D; Warkentin TE; Zytaruk N; Crowther M; Geerts W; Cooper DJ; Vallance S; Qushmaq I; Rocha M; Berwanger O; Vlahakis NE N Engl J Med; 2011 Apr; 364(14):1305-14. PubMed ID: 21417952 [TBL] [Abstract][Full Text] [Related]
3. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group. Kakkar VV; Howes J; Sharma V; Kadziola Z Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310 [TBL] [Abstract][Full Text] [Related]
4. Economic evaluation of the prophylaxis for thromboembolism in critical care trial (E-PROTECT): study protocol for a randomized controlled trial. Fowler RA; Mittmann N; Geerts WH; Heels-Ansdell D; Gould MK; Guyatt G; Krahn M; Finfer S; Pinto R; Chan B; Ormanidhi O; Arabi Y; Qushmaq I; Rocha MG; Dodek P; McIntyre L; Hall R; Ferguson ND; Mehta S; Marshall JC; Doig CJ; Muscedere J; Jacka MJ; Klinger JR; Vlahakis N; Orford N; Seppelt I; Skrobik YK; Sud S; Cade JF; Cooper J; Cook D; ; Trials; 2014 Dec; 15():502. PubMed ID: 25528663 [TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients. Fowler RA; Mittmann N; Geerts W; Heels-Ansdell D; Gould MK; Guyatt G; Krahn M; Finfer S; Pinto R; Chan B; Ormanidhi O; Arabi Y; Qushmaq I; Rocha MG; Dodek P; McIntyre L; Hall R; Ferguson ND; Mehta S; Marshall JC; Doig CJ; Muscedere J; Jacka MJ; Klinger JR; Vlahakis N; Orford N; Seppelt I; Skrobik YK; Sud S; Cade JF; Cooper J; Cook D; ; JAMA; 2014 Nov; 312(20):2135-45. PubMed ID: 25362228 [TBL] [Abstract][Full Text] [Related]
6. Dalteparin versus enoxaparin for venous thromboembolism prophylaxis in acute spinal cord injury and major orthopedic trauma patients: 'DETECT' trial. Slavik RS; Chan E; Gorman SK; de Lemos J; Chittock D; Simons RK; Wing PC; Ho SG J Trauma; 2007 May; 62(5):1075-81; discussion 1081. PubMed ID: 17495705 [TBL] [Abstract][Full Text] [Related]
7. Pharmacological venous thromboembolism prophylaxis in hospitalized medical patients: a meta-analysis of randomized controlled trials. Wein L; Wein S; Haas SJ; Shaw J; Krum H Arch Intern Med; 2007 Jul; 167(14):1476-86. PubMed ID: 17646601 [TBL] [Abstract][Full Text] [Related]
8. Dalteparin: new indication. Prophylaxis in medical patients: no advance. Prescrire Int; 2005 Feb; 14(75):14-5. PubMed ID: 15751168 [TBL] [Abstract][Full Text] [Related]
9. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Leizorovicz A; Cohen AT; Turpie AG; Olsson CG; Vaitkus PT; Goldhaber SZ; Circulation; 2004 Aug; 110(7):874-9. PubMed ID: 15289368 [TBL] [Abstract][Full Text] [Related]
10. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. Lee AY; Levine MN; Baker RI; Bowden C; Kakkar AK; Prins M; Rickles FR; Julian JA; Haley S; Kovacs MJ; Gent M; N Engl J Med; 2003 Jul; 349(2):146-53. PubMed ID: 12853587 [TBL] [Abstract][Full Text] [Related]
11. Low-molecular-weight heparin (dalteparin) in women with gynecologic malignancy. DeBernardo RL; Perkins RB; Littell RD; Krasner CN; Duska LR Obstet Gynecol; 2005 May; 105(5 Pt 1):1006-11. PubMed ID: 15863537 [TBL] [Abstract][Full Text] [Related]
12. [Conventional or low molecular weight heparin in the treatment of venous thromboembolic disease?]. Ruiz Manzano J; Monreal M Med Clin (Barc); 1998 Nov; 111(18):697-9. PubMed ID: 9887434 [No Abstract] [Full Text] [Related]
13. Competing Risk Analysis for Evaluation of Dalteparin Versus Unfractionated Heparin for Venous Thromboembolism in Medical-Surgical Critically Ill Patients. Li G; Cook DJ; Levine MAH; Guyatt G; Crowther M; Heels-Ansdell D; Holbrook A; Lamontagne F; Walter SD; Ferguson ND; Finfer S; Arabi YM; Bellomo R; Cooper DJ; Thabane L; Medicine (Baltimore); 2015 Sep; 94(36):e1479. PubMed ID: 26356708 [TBL] [Abstract][Full Text] [Related]
14. A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis. Luomanmäki K; Grankvist S; Hallert C; Jauro I; Ketola K; Kim HC; Kiviniemi H; Koskivirta H; Sörskog L; Vilkko P J Intern Med; 1996 Aug; 240(2):85-92. PubMed ID: 8810934 [TBL] [Abstract][Full Text] [Related]
15. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Monreal M; Lafoz E; Olive A; del Rio L; Vedia C Thromb Haemost; 1994 Jan; 71(1):7-11. PubMed ID: 8165649 [TBL] [Abstract][Full Text] [Related]
16. [Thromboembolisms endanger the internist patients, too: who needs heparin]. Bischoff A MMW Fortschr Med; 2006 Mar; 148(11):21-2. PubMed ID: 16612959 [No Abstract] [Full Text] [Related]
17. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients. Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080 [TBL] [Abstract][Full Text] [Related]
19. What is the optimal pharmacological prophylaxis for the prevention of deep-vein thrombosis and pulmonary embolism in patients with acute ischemic stroke? Kamphuisen PW; Agnelli G Thromb Res; 2007; 119(3):265-74. PubMed ID: 16674999 [TBL] [Abstract][Full Text] [Related]
20. A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group. Bergmann JF; Neuhart E Thromb Haemost; 1996 Oct; 76(4):529-34. PubMed ID: 8902991 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]